- Home
- NAUT vs CNTX Comparison
NAUT vs CNTX Comparison
Compare NAUT & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAUT | CNTX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.7M | 283.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NAUT | CNTX |
|---|---|---|
| Price | $2.39 | $3.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $4.00 | ★ $6.00 |
| AVG Volume (30 Days) | 220.0K | ★ 910.5K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.07 | ★ 69.33 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $992.86 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $0.49 |
| 52 Week High | $3.08 | $3.62 |
Technical Indicators
Market Signals| Indicator | NAUT | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 60.90 |
| Support Level | $1.82 | $2.07 |
| Resistance Level | $3.08 | N/A |
| Average True Range (ATR) | 0.27 | 0.28 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 23.08 | 62.66 |
Price Performance
Historical ComparisonAbout NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.